阿替利珠单抗联合贝伐珠单抗、卡铂和紫杉醇治疗EGFR突变NSCLC患者TKI治疗失败后的II期研究(NEJ043研究)
这项II期研究评估阿替利珠单抗联合贝伐珠单抗、卡铂和紫杉醇(ABCP)方案在EGFR突变非鳞NSCLC患者TKI治疗失败后的疗效,共纳入26个中心的60例患者。中位无进展生存期为7.4个月,中位总生存期为23.1个月,客观缓解率为55.9%。研究未达到主要终点,但ABCP显示出有临床意义的疗效。
要点
- ABCP方案在EGFR突变NSCLC患者TKI治疗失败后中位PFS为7.4个月,中位OS为23.1个月,ORR为55.9%。
- 一线使用奥希替尼、合并脑转移或肝转移的患者PFS显著更短。
- 研究未达到主要终点,但ABCP显示出有临床意义的疗效。
核心结论
- 研究未达到主要终点,但ABCP在EGFR突变NSCLC患者TKI治疗失败后显示出有临床意义的疗效。
研究设计与样本
- 这是一项II期研究,纳入携带敏感EGFR突变的非鳞NSCLC患者,来自26个中心,共60例。
- ABCP方案每3周给药一次,共4个周期,随后以阿替利珠单抗和贝伐珠单抗维持治疗。
- 主要终点为根据院外审查(ER)评估的无进展生存期(PFS)。
- 关键次要终点和预设分析包括总生存期(OS)、客观缓解率(ORR),以及根据既往EGFR-TKI用药、肝转移和脑转移情况分析ABCP疗效差异。
主要发现
- 中位PFS为7.4个月(95%CI:5.7-8.2)。
- 中位OS为23.1个月(95%CI:13.1-未达到),ORR为55.9%。
- 一线使用奥希替尼的患者PFS显著更短(7.2个月 vs 7.4个月,HR 1.932,p=0.023)。
- 合并脑转移的患者PFS显著更短(5.7个月 vs 8个月,HR 1.86,p=0.032)。
- 合并肝转移的患者PFS显著更短(5.4个月 vs 7.9个月,HR 2.779,p=0.003)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Treatment options for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after EGFR-tyrosine kinase inhibitor (TKI) treatment failure are limited. An exploratory analysis of 26 patients in the IMpower150 study indicated that treatment with atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) was effective in patients with EGFR-mutated NSCLC. This phase II study was conducted to assess the efficacy of ABCP in EGFR-mutated NSCLC patients after TKI treatment. METHODS: Patients with non-squamous NSCLC harboring sensitizing EGFR mutations were enrolled. ABCP therapy was administered every 3 weeks for four cycles, followed by maintenance therapy with atezolizumab and bevacizumab. The primary endpoint was progression-free survival (PFS) according to extramural review (ER). Key secondary endpoints and preplanned analysis included overall survival (OS), overall response rate (ORR), and differences in the efficacy of ABCP according to prior EGFR-TKI administration, liver metastases, and brain metastases. RESULTS: Sixty patients from 26 centers were enrolled. Median PFS was 7.4 months (95% confidence interval [CI]: 5.7-8.2). The median OS was 23.1 months (95% CI: 13.1-not reached), and the ORR was 55.9%. PFS was significantly shorter in patients who had received osimertinib as a first-line treatment (7.2 months vs. 7.4 months, hazard ratio [HR] 1.932, p = 0.023), those with brain metastases (5.7 months vs. 8 months, HR 1.86, p = 0.032), or those with liver metastases (5.4 months vs. 7.9 months, HR 2.779, p = 0.003). CONCLUSIONS: Although this study did not meet the primary endpoint, ABCP showed clinically meaningful efficacy in EGFR-mutated NSCLC patients.
引用
- Watanabe S, Furuya N, Nakamura A, et al. A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study). Eur J Cancer. 2023. PMID: 38061214. doi:10.1016/j.ejca.2023.113469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。